AIM
VNDA icon

Acrospire Investment Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Acrospire Investment Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2,557
Closed -$42K – 1384
2017
Q2 		$42K Sell
2,557
-3,400
-57% -$49K 0.04% 1024
2017
Q1 		$83K Sell
5,957
-16,730
-74% -$238K 0.07% 458
2016
Q4 		$362K Buy
22,687
+12,793
+129% +$206K 0.15% 79
2016
Q3 		$165K Buy
9,894
+1,516
+18% +$20.4K 0.11% 232
2016
Q2 		$94K Sell
8,378
-3,822
-31% -$37K 0.07% 507
2016
Q1 		$102K Buy
+12,200
New +$100K 0.07% 313

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RCAMU
Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acrospire Investment Management's VNDA Position: Q3 2017 in Review

Acrospire Investment Management sold out of Vanda Pharmaceuticals (VNDA) in Q3 2017, closing a stake of 2,557 shares — an estimated $42K sold.

Acrospire Investment Management first reported a position in VNDA in Q1 2016 and held it in 6 quarters. The position peaked at $362K in Q4 2016. 137 funds tracked by Wall St. Rank hold VNDA as of Q3 2017.

  • Acrospire Investment Management reported no remaining Vanda Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 2,557 Vanda Pharmaceuticals shares in Q3 2017, an estimated $42K.
  • Acrospire Investment Management first reported a position in Vanda Pharmaceuticals in Q1 2016 and held it in 6 quarters.
  • Acrospire Investment Management's Vanda Pharmaceuticals position peaked at $362K in Q4 2016.
  • 137 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.